Leaders:
Prof Erwin Dreesen (WG2 Leader)
Dr Elisabet Nielsen (WG2 Co-Leader)
Objectives:
This WG will investigate the individualised treatment optimisation of therapeutic antibodies in chronic inflammatory diseases. More specifically, this WG will focus on deriving therapeutic windows for different therapeutic antibodies in different diseases from large patient cohorts, developing population pharmacokineticpharmacodynamic models and simulations, and deducing guidelines/algorithms for TDM-guided dose optimisation. This will require the selection of the most relevant data, such as patient/disease characteristics, clinical outcomes, surrogate markers of disease activity, time point for blood sampling etc., that will be useful for pharmacokinetic-pharmacodynamic analyses.
Tasks and activities:
- T1: Collect information from previously performed studies on therapeutic windows of different therapeutic antibodies in chronic inflammatory diseases, review the state-of-the-art and identify remaining knowledge gaps.
- T2: Initiate collaborations (with help of structured overview on participating hospitals/research centres from WG3) for (retrospective) data analysis.
- T3: Establish an optimal therapeutic window for the different therapeutic antibodies used in different chronic inflammatory diseases.
- T5: Develop population pharmacokinetic-pharmacodynamic models and simulations for the different therapeutic antibodies used in the different diseases.
- T7: Develop guidelines on dose optimisation of therapeutic antibodies to reach serum drug concentrations within the therapeutic window for an optimal response to treatment.
Deliverables:
- D1: Publication of review(s) on the state-of-the-art and remaining knowledge gaps on therapeutic windows of therapeutic antibodies in chronic inflammatory diseases.
- D2: Publications on therapeutic windows of therapeutic antibodies used in the different chronic inflammatory diseases.
- D3: Publications on the population pharmacokinetic-pharmacodynamic models and simulation for therapeutic antibodies in different diseases.
- D4: Publication of guidelines on individualised TDM-guided dose optimisation.
- D5: Submission of at least 1 new collaborative research project proposal.